Cancer Drugmaker Apollomics Agrees to Merge with Maxpro SPAC
Cancer drugmaker, Apollomics Inc., agreed to go public through a merger with SPAC Maxpro Capital Acquisition Corp. The deal values the company at about $1 billion.
Apollomics is working on nine types of drugs for difficult-to-treat forms of lung cancer and leukemia.
Read more on Mergers & Acquisitions…
Shanda Consult has been working with SPACs for many years, and our network of SPAC executives has deep experience in the sector. If you need to learn more about how to successfully use a SPAC structure and perhaps wish to set up your own SPAC, we are here to help.
Please contact us with any questions you may have.
Recent Posts
- Nasdaq approves Breeze Holdings’ acquisition for continued listing to complete a deal by May 28
- AirAsia owner Capital A International is combining with Aetherium acquisition in a $1.15 billion deal
- $60 Million PIPE to Support Zooz Deal is being negotiated by Keyarch Acquisition
- BitFuFu, a Bitcoin mining startup sponsored by Bitmain, intends to go public through a SPAC offering
- Following SPAC merger Bitcoin miner GRIID makes NASDAQ debut